Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Deferred Revenue: 2012-2021

Historic Current Deferred Revenue for Ani Pharmaceuticals (ANIP) over the last 6 years, with Dec 2021 value amounting to $100,000.

  • Ani Pharmaceuticals' Current Deferred Revenue rose 16.00% to $116,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $116,000, marking a year-over-year increase of 16.00%. This contributed to the annual value of $100,000 for FY2021, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2021, Ani Pharmaceuticals' Current Deferred Revenue is $100,000, which was down 0.00% from $100,000 recorded in FY2020.
  • In the past 5 years, Ani Pharmaceuticals' Current Deferred Revenue ranged from a high of $711,000 in FY2018 and a low of $100,000 during FY2020.
  • For the 3-year period, Ani Pharmaceuticals' Current Deferred Revenue averaged around $233,333, with its median value being $100,000 (2021).
  • Data for Ani Pharmaceuticals' Current Deferred Revenue shows a maximum YoY crashed of 80.00% (in 2020) over the last 5 years.
  • Over the past 4 years, Ani Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $711,000 in 2018, then declined by 29.68% to $500,000 in 2019, then tumbled by 80.00% to $100,000 in 2020, then remained steady at $100,000 in 2021.